These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 21288201)

  • 41. Myeloproliferative Neoplasms.
    Spivak JL
    N Engl J Med; 2017 Jun; 376(22):2168-2181. PubMed ID: 28564565
    [No Abstract]   [Full Text] [Related]  

  • 42. [Chronic myeloproliferative conditions and chronic myeloid leukemia (new findings and views)].
    Chrobák L
    Vnitr Lek; 1987 Oct; 33(10):919-26. PubMed ID: 3318100
    [No Abstract]   [Full Text] [Related]  

  • 43. Familial occurrence of sequential B-cell lymphoma and myeloproliferative disease.
    Au WY; Leung R; Mok T; Fung A; Liang R
    Ann Hematol; 2008 Nov; 87(11):931-2. PubMed ID: 18521603
    [No Abstract]   [Full Text] [Related]  

  • 44. [Molecularly pathogenesis and molecular targeted therapy for myeloproliferative neoplasms].
    Shide K
    Rinsho Ketsueki; 2015 Feb; 56(2):150-8. PubMed ID: 25765794
    [TBL] [Abstract][Full Text] [Related]  

  • 45. [Overview--Recent therapeutic strategy for hematologic disorders of bone marrow].
    Inokuchi K
    Rinsho Ketsueki; 2014 Jan; 55(1):29-30. PubMed ID: 24492034
    [No Abstract]   [Full Text] [Related]  

  • 46. Myeloproliferative disorders in pregnancy.
    Harrison CN; Robinson SE
    Hematol Oncol Clin North Am; 2011 Apr; 25(2):261-75, vii. PubMed ID: 21444029
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Current world literature.
    Curr Opin Hematol; 2011 Mar; 18(2):124-31. PubMed ID: 21307671
    [No Abstract]   [Full Text] [Related]  

  • 48. [Cytogenetic studies on myeloproliferative disorder].
    Taniwaki M; Misawa S
    Rinsho Ketsueki; 1988 Jul; 29(7):1001-9. PubMed ID: 3184467
    [No Abstract]   [Full Text] [Related]  

  • 49. Translocation t(8;13) in a patient with T cell lymphoma and features of a myeloproliferative syndrome.
    Behringer D; Schaefer HE; Kunzmann R; Mertelsmann R; Dölken G
    Leukemia; 1995 Jun; 9(6):988-92. PubMed ID: 7596190
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Transient myeloproliferative disorder in chromosomally normal newborn infant.
    Kalousek DK; Chan KW
    Med Pediatr Oncol; 1987; 15(1):38-41. PubMed ID: 2951583
    [TBL] [Abstract][Full Text] [Related]  

  • 51. [Histological diagnosis of Ph-negative myeloproliferative neoplasia. An overview].
    Campr V
    Cesk Patol; 2011 Jul; 47(3):84-93. PubMed ID: 21887923
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Inv(1)(p22q25) in chronic myeloproliferative disease: constitutional or clonal defect?
    Wong KF; Wong WC; Cheuk W
    Cancer Genet Cytogenet; 2005 Apr; 158(2):188-91. PubMed ID: 15796968
    [TBL] [Abstract][Full Text] [Related]  

  • 53. The recent advances in classic BCR-ABL-negative myeloproliferative disorders.
    Tefferi A
    Clin Adv Hematol Oncol; 2007 Feb; 5(2):113-5. PubMed ID: 17344799
    [No Abstract]   [Full Text] [Related]  

  • 54. Molecular pathology of myeloproliferative neoplasms.
    Klco JM; Vij R; Kreisel FH; Hassan A; Frater JL
    Am J Clin Pathol; 2010 Apr; 133(4):602-15. PubMed ID: 20231614
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Neonatal vesiculopustular eruption of the face: a sign of trisomy 21-associated transient myeloproliferative disorder.
    Moriuchi R; Shibaki A; Yasukawa K; Onozuka T; Sato T; Kaneda M; Iguchi A; Kobayashi R; Shimizu H
    Br J Dermatol; 2007 Jun; 156(6):1373-4. PubMed ID: 17459046
    [No Abstract]   [Full Text] [Related]  

  • 56. ALK fusion genes in children with atypical myeloproliferative leukemia.
    Röttgers S; Gombert M; Teigler-Schlegel A; Busch K; Gamerdinger U; Slany R; Harbott J; Borkhardt A
    Leukemia; 2010 Jun; 24(6):1197-200. PubMed ID: 20428197
    [No Abstract]   [Full Text] [Related]  

  • 57. Recurrent Cytogenetic Abnormalities in Myeloproliferative Neoplasms and Chronic Myeloid Leukemia.
    Swansbury J
    Methods Mol Biol; 2017; 1541():247-256. PubMed ID: 27910028
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Oncogenic kinases of myeloproliferative disorders induce both protein synthesis and G1 activators.
    Lelièvre H; Cervera N; Finetti P; Delhommeau F; Vainchenker W; Bertucci F; Birnbaum D
    Leukemia; 2006 Oct; 20(10):1885-8. PubMed ID: 16900207
    [No Abstract]   [Full Text] [Related]  

  • 59. Advances in the molecular characterization of Philadelphia-negative chronic myeloproliferative disorders.
    Pikman Y; Levine RL
    Curr Opin Oncol; 2007 Nov; 19(6):628-34. PubMed ID: 17906464
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Therapy-related myeloid neoplasms.
    Larson RA
    Haematologica; 2009 Apr; 94(4):454-9. PubMed ID: 19336749
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.